Non-intrusive Detection of Temporary Neurologic Impairment by Opioids

Z

Zxerex

Status

Completed

Conditions

Neurologic Impairment by Opioids

Treatments

Drug: Oxycodone

Study type

Observational

Funder types

Industry

Identifiers

NCT05489601
OpioidsPhaseI

Details and patient eligibility

About

The investigators aim to prove the feasibility of a non-invasive means to identify temporary neurological impairment resulting from the use of a commonly prescribed opioid by identifying an oculomotor biosignature associated with temporary neurologic impairment in pain-free opioid-naïve subjects, and to initiate the development of such a signature. The investigators also sought to establish the presence of a dose-dependent biosignature for opioid impairment.

Full description

To determine the detrimental effects of opioid intoxication on normal oculomotor function, the investigators will collect data from up to 25 subjects before and during oxycodone induced intoxication. A within-subjects design will be used, and subjects will be tested under conditions of no dose (placebo), low dose, and high dose. Subjects will be tested during 3 sessions (baseline, placebo, oxycodone); separated by 7 days to allow for complete washout of any drug that was administered. Subjects will perform tests of visual fixation, saccade speed and saccade accuracy, cognitive control over saccades, cognitive control over visual scanning, and visual pursuit. Eye movement data will be collected using an SR Research EyeLink 1000 Plus eye tracking system. Analysis of the data will be performed by comparing each subject state against the baseline measurements, where baseline represents an unimpaired subject state. Based on prior work with marijuana intoxication, the investigators expect that this data and analysis will successfully reveal a constellation of oculomotor dynamics that can be used to classify whether an individual is or is not currently impaired by oxycodone. Based on published studies, the investigators anticipate these changes will generalize across the opioid class, creating a biosignature of opioid impairment.

Enrollment

17 patients

Sex

All

Ages

21 to 59 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Adults between 21 and 59 years of age.
  • Males and females; women must practice an effective form of birth control (condoms, diaphragm, birth control pill, IUD).

Exclusion criteria

  • Prior use of any opioids during the preceding 30 days.
  • Positive urine drug test for any drug at any point during the study.
  • Pregnancy

Trial design

17 participants in 1 patient group

Participants
Description:
Adults between 21 and 59 years of age. Males and females; women must practice an effective form of birth control (condoms, diaphragm, birth control pill, IUD). Subjects have taken an opioid prescription for pain management within the prior 24 months and have not used any opioids during the preceding 30 days. Subjects are required to have a negative urine drug test. At any point during the study, If a subject is found to have a positive drug test, the subject will be discontinued from the study.
Treatment:
Drug: Oxycodone

Trial documents
1

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems